Matthew Majewski

Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.

In the second of a three part series about the Inflation Reduction Act, Matthew Majewski and Rhett Johnson of Charles River Associates review the provisions of the law that will affect medication pricing and reimbursement, including Medicare price negotiation.

Matthew Majewski and Rhett Johnson of Charles River Associates explain some of the provisions of the Inflation Reduction Act and what they mean for life sciences companies.